It's great that the company derives revenue from it's association with BARDA. But you can't ignore that that revenue would not even exist if not for the reimbursement of costs. In FY 18, the company realized $3.827 million from the BARDA contract. At the same time it spent $3.806 million on research and development. Now, it's certain that not the entirety of this expense was BARDA related, but it is likely that the BARDA-related expense was at least $3.4 million in order to justify revenues of the order indicated. Thus, it's likely that the BARDA-related net revenue was in the order of $200,000, based on a typical fee structure of about 6%.
- Forums
- ASX - By Stock
- Polynovo’s Novosorb is a med-tech Swiss Army Knife
PNV
polynovo limited
Add to My Watchlist
0.42%
!
$1.20

It's great that the company derives revenue from it's...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.20 |
Change
0.005(0.42%) |
Mkt cap ! $829.0M |
Open | High | Low | Value | Volume |
$1.21 | $1.24 | $1.19 | $1.649M | 1.366M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16990 | $1.20 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.21 | 9989 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16990 | 1.200 |
1 | 25000 | 1.195 |
4 | 87354 | 1.190 |
2 | 12607 | 1.185 |
2 | 13048 | 1.180 |
Price($) | Vol. | No. |
---|---|---|
1.210 | 9989 | 1 |
1.215 | 9083 | 1 |
1.220 | 9083 | 1 |
1.225 | 63084 | 2 |
1.230 | 30723 | 4 |
Last trade - 16.10pm 01/07/2025 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
AFP
AFT PHARMACEUTICALS LIMITED
Dr. Hartley Atkinson, MD
Dr. Hartley Atkinson
MD
Previous Video
Next Video
SPONSORED BY The Market Online